Overview

Quality of Life on Peritoneal Dialysis Versus Hemodialysis in China

Status:
Completed
Trial end date:
2017-09-18
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, open-label study to compare QoL in subjects with end-stage renal disease (ESRD) requiring PD or conventional in-center HD treatment. Primary Objective: The primary objective is to demonstrate non-inferiority of peritoneal dialysis (PD) treatment as compared to hemodialysis (HD) treatment after approximately 1 year of therapy using the Kidney Disease Quality of Life-Short Form (KDQoL-SF) questionnaire domain of burden of kidney disease. Secondary Objectives: The secondary objectives are to observe and summarize the following parameters in subjects receiving PD or HD treatment except for the remaining domains of QoL instrument KDQoL-SF™ (version 1.3) and the 2 individual QoL items scored as single items, which will be compared between the 2 treatment groups: - Mortality rates - Switch (PD to HD or HD to PD) - Transplantation rate - Cause of death - Dialysis adequacy (ie, urea clearance time normalized by total body water, which is the volume of distribution of urea [Kt/V urea] to determine the proportion of subjects meeting standards of care for dialysis adequacy). - 24-hour urine volume - Change in hemoglobin and S-phosphate levels, and the percentages of subjects with values within the target range - Change in serum albumin - Frequency of adverse events (AEs) and serious AEs (SAEs), including abnormal laboratory test findings with clinical significance
Phase:
Phase 4
Details
Lead Sponsor:
Baxter Healthcare Corporation